Ads
related to: t-cell therapy
Search results
CAR T-Cell therapy revolutionised landscape of cancer treatment: Doctors
Investing.com· 1 day agoNew Delhi, May 21 (IANS) A 42-year-old man from Bengaluru has successfully achieved "durable...
MRD endpoint expected to usher new era for MM therapies
Clinical Trials Arena via Yahoo Finance· 1 hour agoDr. Durie added that new immune therapies like chimeric antigen receptor (CAR)-T cell therapies and...
AmplifyBio and Xcell enter TCR T-cell therapy manufacturing deal
Pharmaceutical Technology via Yahoo Finance· 1 day agoEditorial content is independently produced and follows the highest standards of journalistic...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 hours agoCaptain T Cell GmbH, a biotechnology company developing next-generation T cells against solid tumors, today announced the successful closing of a seed financing ...
Earnings call: Adaptimmune outlines afami-cel launch and financials By Investing.com
Investing.com· 7 days agoAdaptimmune Therapeutics PLC (NASDAQ:ADAP), a biotechnology company specializing in T-cell therapy,...
Keeping CAR T Cells Sharp
The Scientist· 1 day agoResearchers have observed that certain types of CAR T cells are more effective at eradicating cancer. One especially advantageous quality is a...
Anixa advances CAR-T trial for ovarian cancer with fifth patient By Investing.com
Investing.com· 20 hours agoAnixa Biosciences, Inc. (NASDAQ: NASDAQ:ANIX), a clinical-stage biotechnology company, has begun...
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration...
Morningstar· 6 days agoBristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular ...
ImmPACT Bio to Present New Preclinical Data for CD19/CD20 Bispecific CAR-T Cell Therapy in Multiple...
FOX 23 News Albany· 1 day agoImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to ...
...IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF...
Morningstar· 6 days agoBreakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and ...